NDC product
Evista
NDC 0002-4184 · Eli Lilly and Company
Key facts
| Product NDC | 0002-4184 |
|---|---|
| Proprietary name | Evista |
| Nonproprietary name | Raloxifene hydrochloride |
| Substances | RALOXIFENE HYDROCHLORIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Eli Lilly and Company |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA020815 |
| Pharmacologic classes | Estrogen Agonist/Antagonist [EPC], Selective Estrogen Receptor Modulators [MoA] |
| Marketing start | Jan 6, 1998 |
| Marketing end | Jul 10, 2028 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory